These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3044063)

  • 21. Allogeneic bone marrow transplantation for acute leukaemia: comparative outcomes for adults and children.
    Weisdorf DJ; McGlave PB; Ramsay NK; Miller WJ; Nesbit ME; Woods WG; Goldman AI; Kim TH; Kersey JH
    Br J Haematol; 1988 Jul; 69(3):351-8. PubMed ID: 3044439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late onset of renal dysfunction in survivors of bone marrow transplantation.
    Tarbell NJ; Guinan EC; Niemeyer C; Mauch P; Sallan SE; Weinstein HJ
    Int J Radiat Oncol Biol Phys; 1988 Jul; 15(1):99-104. PubMed ID: 2968967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypertriglyceridemia in bone marrow transplant recipients: another side effect of cyclosporine A.
    Carreras E; Villamor N; Reverter JC; Sierra J; Grañena A; Rozman C
    Bone Marrow Transplant; 1989 Jul; 4(4):385-8. PubMed ID: 2673458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease.
    Przepiorka D; Shapiro S; Schwinghammer TL; Bloom EJ; Rosenfeld CS; Shadduck RK; Venkataramanan R
    Bone Marrow Transplant; 1991 Jun; 7(6):461-5. PubMed ID: 1873593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
    Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation.
    Antignac C; Gubler MC; Leverger G; Broyer M; Habib R
    Kidney Int; 1989 Jun; 35(6):1336-44. PubMed ID: 2671466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclosporin-A in allogeneic bone marrow transplantation for leukemia: Basle experience 1979 to 1984.
    Gratwohl A
    Tokai J Exp Clin Med; 1985 Jun; 10(2-3):127-32. PubMed ID: 3914737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
    Matsuyama T; Kojima S; Kato K
    Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary characterization of functional residual host-type T lymphocytes following conditioning for allogeneic HLA-matched bone marrow transplantation (BMT).
    Kedar E; Or R; Naparstek E; Zeira E; Slavin S
    Bone Marrow Transplant; 1988 Mar; 3(2):129-40. PubMed ID: 3048477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases.
    Rosales F; Peylan-Ramu N; Cividalli G; Varadi G; Or R; Naparstek E; Slavin S; Nagler A
    Bone Marrow Transplant; 1999 May; 23(9):861-5. PubMed ID: 10338039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study.
    Woods WG; Kobrinsky N; Buckley J; Neudorf S; Sanders J; Miller L; Barnard D; Benjamin D; DeSwarte J; Kalousek D
    J Clin Oncol; 1993 Aug; 11(8):1448-57. PubMed ID: 8336184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation by mycophenolate mofetil in a murine model].
    Huang H; Zheng W; Lin M; Fu J; Zhang R
    Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):191-3. PubMed ID: 12133455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic bone marrow transplantation for leukaemia in Europe. Report from the Working Party on Leukaemia, European Group for Bone Marrow Transplantation.
    Lancet; 1988 Jun; 1(8599):1379-82. PubMed ID: 2898053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
    Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
    Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclosporine-induced encephalopathy in a patient with relapsed acute myeloid leukemia treated with unrelated allogeneic bone marrow transplantation.
    Chen YC; Chao TY; Chen CY; Ho CL
    J Formos Med Assoc; 2000 Mar; 99(3):248-51. PubMed ID: 10820959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
    Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
    Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.